$995.20 general Payment -- Gilead Sciences to Dr. Laura Hall

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Gilead Sciences made a $995.20 general payment to Laura Hall, a HIV Medicine specialist in City, MO. The payment was associated with Rinvoq. Laura Hall received $995.20 from Gilead Sciences on November 17, 2025. The payment was for services other than consulting, specifically related to the drug Rinvoq. This payment falls under the 'general' payment type in the CMS Open Payments program.

Patient Guidance: What This Payment Means for You

This payment to your physician is for services related to a medication and is publicly reported by CMS. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for services other than consulting in HIV Medicine can vary, but this specific amount is on the lower end for general service compensation.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

• cms-open-payments
• pharmaceutical-payments
• physician-compensation
• hiv-medicine
• gilead-sciences
• rinvoq

Understanding general Payments

general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.

Frequently Asked Questions About This Payment

What was this $995.20 payment for?

This was a general payment of $995.20 from Gilead Sciences to Laura Hall, categorized as "Compensation for services other than consulting". It was associated with Rinvoq. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Laura Hall accept pharmaceutical money?

Yes, Laura Hall received this $995.20 payment from Gilead Sciences. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Laura Hall's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this general payment?

A general payment of $995.20 should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in HIV Medicine?

To compare this payment against HIV Medicine averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. HIV Medicine physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Laura Hall's relationship with Gilead Sciences?

The payment amount is relatively modest. This $995.20 general payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for HIV Medicine?

The payment is for services rendered, not for consulting or speaking.

What should patients do after learning about this payment?

This payment to your physician is for services related to a medication and is publicly reported by CMS.

What else should I know about this general payment?

The payment is associated with the drug Rinvoq.

Related Reports

• View Dr. Laura Hall's full payment report
• Gilead Sciences full spending report
• Browse all HIV Medicine payments
• Browse all payments in Missouri
• Search for other payments